Rossi X-ray Timing Explorer Observations of the X-ray Pulsar EXO 1722-363 - a Candidate Eclipsing Supergiant System

Observations made of the X-ray pulsar EXO 1722-363 using the Proportional Counter Array and All Sky Monitor on board the Rossi X-ray Timing Explorer reveal the orbital period of this system to be 9.741 +/- 0.004 d from periodic changes in the source flux. The detection of eclipses, together with the values of the pulse and orbital periods, suggest that this source consists of a neutron star accreting from the stellar wind of an early spectral type supergiant companion. Pulse timing measurements were also obtained but do not strongly constrain the system parameters. The X-ray spectra can be well fitted with a model consisting of a power law with a high energy cutoff and, for some spectra, a blackbody component with a temperature of approximately 0.85 keV.Comment: Accepted for publication in The Astrophysical Journal. 27 pages including 10 figure

Image potential states as quantum probe of graphene interfaces

Image potential states (IPSs) are electronic states localized in front of a surface in a potential well formed by the surface projected bulk band gap on one side and the image potential barrier on the other. In the limit of a two-dimensional solid a double Rydberg series of IPSs has been predicted which is in contrast to a single series present in three-dimensional solids. Here, we confirm this prediction experimentally for mono- and bilayer graphene. The IPSs of epitaxial graphene on SiC are measured by scanning tunnelling spectroscopy and the results are compared to ab-initio band structure calculations. Despite the presence of the substrate, both calculations and experimental measurements show that the first pair of the double series of IPSs survives, and eventually evolves into a single series for graphite. Thus, IPSs provide an elegant quantum probe of the interfacial coupling in graphene systems.Comment: Accepted for publication in New Journal of Physic

The Grizzly, March 26, 1982

Dr. Eugene Miller Retires This Spring • Board Names Council Chairman • SPC Elects Hanlon as New Grizzly Editor • News Briefs: Huggers Needed!; Take Action Against Financial Aid Cuts; UC Food Day Helps Fight World Hunger • Think Tank Discusses Energy Conservation • Production of Vanities • New Dates for UC Photo Class • Hooters at UC for Concert • What\u27s Around Town on the Silver Screen • USGA Notes • Sports Brief: W\u27s Tennis Ready to Go; Field Hockey Back From England • W\u27s Track Club is Tough • Batman Drop Close One • M\u27s Lacrosse Looking Tough • UC Track Team Explodes for Big Win • Veterans Plus Youth Equals Excitement • W\u27s Lacrosse Opens With Victoryhttps://digitalcommons.ursinus.edu/grizzlynews/1076/thumbnail.jp

Milling plant and soil material in plastic tubes over-estimates carbon and under-estimates nitrogen concentrations

Peer reviewedPostprin

How COVID-19 has fundamentally changed clinical research in global health

COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have been registered that are of questionable methodological quality. As the final paper of this Series, we discuss how the medical research community has responded to COVID-19. We recognise the incredible pressure that this pandemic has put on researchers, regulators, and policy makers, all of whom were doing their best to move quickly but safely in a time of tremendous uncertainty. However, the research community\u27s response to the COVID-19 pandemic has prominently highlighted many fundamental issues that exist in clinical trial research under the current system and its incentive structures. The COVID-19 pandemic has not only re-emphasised the importance of well designed randomised clinical trials but also highlighted the need for large-scale clinical trials structured according to a master protocol in a coordinated and collaborative manner. There is also a need for structures and incentives to enable faster data sharing of anonymised datasets, and a need to provide similar opportunities to those in high-income countries for clinical trial research in low-resource regions where clinical trial research receives considerably less research funding